OraSure Technologies (NASDAQ:OSUR) Stock Rating Upgraded by StockNews.com

OraSure Technologies (NASDAQ:OSUR) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Friday.

OSUR has been the topic of a number of other research reports. Evercore ISI upped their price target on shares of OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research note on Wednesday. JPMorgan Chase & Co. decreased their price target on shares of OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, OraSure Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

OraSure Technologies Trading Down 8.1 %

Shares of OraSure Technologies stock traded down $0.37 during trading on Friday, hitting $4.22. 676,761 shares of the stock were exchanged, compared to its average volume of 1,013,736. The stock has a market capitalization of $312.11 million, a price-to-earnings ratio of 14.07 and a beta of 0.09. The company has a fifty day moving average price of $4.36 and a 200-day moving average price of $5.59. OraSure Technologies has a 1-year low of $3.91 and a 1-year high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share for the quarter, hitting the consensus estimate of $0.04. OraSure Technologies had a net margin of 7.50% and a return on equity of 7.68%. The company had revenue of $54.10 million for the quarter, compared to analyst estimates of $52.27 million. During the same period in the previous year, the business earned $0.37 EPS. OraSure Technologies’s revenue for the quarter was down 65.1% compared to the same quarter last year. Equities research analysts forecast that OraSure Technologies will post -0.08 EPS for the current fiscal year.

Institutional Trading of OraSure Technologies

Institutional investors have recently bought and sold shares of the business. AJOVista LLC bought a new stake in OraSure Technologies in the 4th quarter valued at about $39,000. SG Americas Securities LLC bought a new stake in OraSure Technologies in the 1st quarter valued at about $72,000. Dynamic Technology Lab Private Ltd bought a new stake in OraSure Technologies in the 4th quarter valued at about $113,000. Baader Bank Aktiengesellschaft bought a new stake in OraSure Technologies in the 4th quarter valued at about $115,000. Finally, Tocqueville Asset Management L.P. boosted its holdings in OraSure Technologies by 20.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 2,512 shares during the period. Institutional investors own 93.50% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.